Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,494,697
  • Shares Outstanding, K 122,492
  • Annual Sales, $ 196,540 K
  • Annual Income, $ -140,040 K
  • EBIT $ -38 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.69
  • Price/Sales 18.04
  • Price/Cash Flow N/A
  • Price/Book 22.49

Options Overview Details

View History
  • Implied Volatility 63.47% (-8.70%)
  • Historical Volatility 50.25%
  • IV Percentile 17%
  • IV Rank 16.94%
  • IV High 116.97% on 08/01/25
  • IV Low 52.57% on 08/20/25
  • Expected Move (DTE 2) 1.29 (4.53%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 122
  • Volume Avg (30-Day) 774
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 18,379
  • Open Int (30-Day) 17,402
  • Expected Range 27.24 to 29.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 3
  • High Estimate 0.10
  • Low Estimate -0.05
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +122.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.82 +14.95%
on 11/17/25
31.77 -10.20%
on 12/08/25
+3.53 (+14.12%)
since 11/14/25
3-Month
16.57 +72.18%
on 09/25/25
31.77 -10.20%
on 12/08/25
+11.56 (+68.12%)
since 09/16/25
52-Week
11.13 +156.33%
on 02/11/25
31.77 -10.20%
on 12/08/25
+14.96 (+110.24%)
since 12/16/24

Most Recent Stories

More News
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 28.53 (-1.45%)
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children...

ARQT : 28.53 (-1.45%)
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approved...

ARQT : 28.53 (-1.45%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 28.53 (-1.45%)
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

ZORYVE foam 0.3% was safe, well-tolerated, and demonstrated durable and continuously improving efficacy in the treatment of seborrheic dermatitis up to 52 weeks Once-daily ZORYVE foam 0.3% is approved...

ARQT : 28.53 (-1.45%)
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin health ZORYVE® (roflumilast) is the #1 prescribed branded topical...

ARQT : 28.53 (-1.45%)
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can...

ARQT : 28.53 (-1.45%)
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

  Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025  ZORYVE cream 0.05% received U.S. Food...

ARQT : 28.53 (-1.45%)
Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 28.53 (-1.45%)
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 years New long-term data demonstrate that ZORYVE cream was well-tolerated...

ARQT : 28.53 (-1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 30.24
2nd Resistance Point 29.84
1st Resistance Point 29.18
Last Price 28.53
1st Support Level 28.12
2nd Support Level 27.72
3rd Support Level 27.06

See More

52-Week High 31.77
Last Price 28.53
Fibonacci 61.8% 23.89
Fibonacci 50% 21.45
Fibonacci 38.2% 19.01
52-Week Low 11.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar